Pliant Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 27, 2024. This is an annual report, not a standalone fourth-quarter earnings release. Pliant is a clinical-stage biopharmaceutical company focused on fibrosis. It had no approved products and generated no product-sales revenue.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.6 million | $9.7 million |
| Research and development expense | $127.8 million | $96.9 million |
| General and administrative expense | $57.9 million | $39.9 million |
| Operating loss | $184.1 million | $127.2 million |
| Net loss | $161.3 million | $123.3 million |
| Net loss per share, basic and diluted | $2.75 | $2.94 |
| Net cash used in operating activities | $116.4 million | $94.6 million |
| Cash, cash equivalents and short-term investments | $494.2 million | $331.2 million |
| Cash, cash equivalents and restricted cash | $64.7 million | $33.7 million |
| Long-term debt | $10.1 million | $9.9 million |
Revenue was entirely associated with the Novartis collaboration; the filing reports no product-sales revenue. Gross margin and product margins are therefore not meaningful. Management estimated that existing cash, cash equivalents and short-term investments would fund anticipated operating expenses and capital requirements into the second half of 2026, subject to operating-plan assumptions and changes in spending.
Material changes versus FY2022
- Revenue fell 83.7% as Novartis terminated its collaboration; Pliant recognized research and development services revenue only through April 18, 2023.
- R&D expense rose 31.8%, chiefly from higher employee-related costs and clinical-trial spending, including bexotegrast’s Phase 2b IPF trial and initiation of the PLN-101095 Phase 1 trial.
- G&A expense increased 45.0%, including higher employee-related costs and stock-based compensation.
- Net loss widened 30.8%. Higher interest and other income, primarily from larger investment balances and yields, partly offset increased operating expenses and lower collaboration revenue.
- Operating cash use increased by $21.7 million. Financing cash flow included approximately $269.8 million net proceeds from the January 2023 public offering.
Business, outlook and notable developments
- Bexotegrast: The lead candidate is in a Phase 2b IPF trial and a Phase 2a PSC trial. Pliant reported positive Phase 2a IPF results in 2023 and positive interim PSC results reported in early 2024. The company expected final PSC trial data in mid-2024; the 52-week BEACON-IPF trial was expected to enroll approximately 270 patients.
- Other programs: PLN-101095 was in Phase 1 dose escalation for checkpoint-inhibitor-resistant solid tumors; preliminary data were expected in late 2024. Pliant expected to file for first-in-human studies of PLN-101325 in muscular dystrophies in the first quarter of 2024.
- Novartis/PLN-1474: Novartis returned global rights to PLN-1474 and associated research targets in 2023. Pliant lost eligibility for future milestone and royalty payments under the agreement.
- Capital and debt: The January 2023 equity offering increased cash resources but diluted shareholders. The $10 million Oxford term loan bears interest at one-month SOFR plus 8.5%, subject to a floor and cap; interest-only payments were scheduled through July 1, 2026, followed by principal and interest payments to maturity on May 1, 2027. The loan is secured by substantially all current and future assets, subject to stated exclusions.
- Facilities: Pliant signed a lease for approximately 100,904 square feet at Oyster Point, with an approximately seven-year term beginning after tenant improvements. Future lease payments were approximately $43.7 million, expected to start in the third quarter of 2024. The filing also describes a $1.4 million letter of credit requirement.
- Risks and contingencies: Pliant expects substantial losses and requires additional capital to complete clinical development. Key risks include clinical efficacy and safety uncertainty, patient enrollment, competition, reliance on third parties and a sole-source bexotegrast supplier in Asia (including China), regulatory and reimbursement uncertainty, intellectual-property challenges, and debt and lease obligations. No material legal proceedings were reported.
- Controls and audit: Management and the independent auditor concluded internal control over financial reporting was effective as of year-end; the financial-statement audit opinion was unqualified. The auditor identified accrued and prepaid CRO research and development expenses as a critical audit matter because estimating services performed requires significant judgment.
The filing provides no formal financial guidance for FY2024. The clinical milestones above are management expectations stated in the report and are subject to development, regulatory, enrollment, supply and financing risks.
Key facts for investors to verify
- Progress, enrollment and full results of BEACON-IPF and INTEGRIS-PSC, including whether early-stage signals translate into robust, controlled clinical benefit.
- Actual cash burn and investment balances, and whether the stated runway into the second half of 2026 remains achievable as trial costs and other spending evolve.
- Supply continuity and manufacturing alternatives for bexotegrast, given reliance on third-party and single-source suppliers.
- Terms, commencement and cash impact of the Oyster Point lease, alongside scheduled Oxford loan payments and covenants.
- Potential dilution from equity compensation, future fundraising or use of the company’s registered at-the-market offering capacity.